Approximately 5–15% of CRC patients harbor BRAF mutations, more than 90% of which is BRAF V600E mutation, leading to prolonged activation of the MAPK pathway and promoting tumor progression [2–4]. This evidence concerns the gene BRAF and neoplasm.